A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection.

Trial Profile

A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jan 2016

At a glance

  • Drugs JX 929 (Primary) ; JX 929 (Primary)
  • Indications Breast cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Dec 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 06 Sep 2012 Actual initiation date changed from 1 Feb 2008 to 1 May 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top